<DOC>
	<DOC>NCT01395849</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.</brief_summary>
	<brief_title>Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)</brief_title>
	<detailed_description />
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Must use fluticasone and salmeterol for the first time Patients with hypersensitivity to salmeterol and fluticasone Patients with infection which salmeterol and fluticasone is not effective Patients with deep mycosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>